When compared to controls, the TKI treated mice had 1269 DEGs (Fig. 5B), and a net pro-CML contribution with BCR::ABL the top pro-CML DEG (Fig. 5D). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.